MindMedMNMD
MNMD
About: Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
Employees: 57
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
79% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 28
79% more call options, than puts
Call options by funds: $4.76M | Put options by funds: $2.67M
43% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 21
3% more funds holding
Funds holding: 149 [Q2] → 154 (+5) [Q3]
2.8% more ownership
Funds ownership: 58.07% [Q2] → 60.87% (+2.8%) [Q3]
6% less capital invested
Capital invested by funds: $301M [Q2] → $282M (-$18.9M) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
179%
upside
Avg. target
$32
342%
upside
High target
$55
668%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Rudy Li 0% 1-year accuracy 0 / 4 met price target | 179%upside $20 | Buy Initiated | 20 Dec 2024 |
Oppenheimer Francois Brisebois 40% 1-year accuracy 14 / 35 met price target | 179%upside $20 | Outperform Reiterated | 17 Dec 2024 |
HC Wainwright & Co. Patrick Trucchio 27% 1-year accuracy 42 / 156 met price target | 668%upside $55 | Buy Reiterated | 11 Nov 2024 |
Financial journalist opinion
Based on 3 articles about MNMD published over the past 30 days
Positive
The Motley Fool
1 week ago
Why Mind Medicine Stock Is Soaring Today
Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m.
Positive
Zacks Investment Research
3 weeks ago
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
2024 was a transformational year for MNMD as it executed many important milestones.
Positive
Zacks Investment Research
4 weeks ago
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
Neutral
Business Wire
1 month ago
MindMed to Be Added to the Nasdaq Biotechnology Index
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed. We've successfully executed many important milestones, including raising approximately $250 million.
Neutral
Business Wire
1 month ago
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT v.
Neutral
Business Wire
1 month ago
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company's lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ. Details of the presentations are a.
Neutral
Business Wire
1 month ago
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). The Innovation Passport is the.
Neutral
Business Wire
1 month ago
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 or.
Neutral
Business Wire
1 month ago
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 171,000 common shares of the Company (the "Options"), with effective grant dates of November 18, 2024 and December 2, 2024, depending on the a.
Neutral
Business Wire
2 months ago
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. “We are.
Charts implemented using Lightweight Charts™